FDA approves mobocertinib as the first oral therapy for patients with non-small cell lung cancer with EGFR Exon20 insertion mutations.
List view / Grid view
Dana-Farber Cancer Institute
BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results.
In this article, European Pharmaceutical Review’s Hannah Balfour discusses how COVID-19 has impacted the pharma industry with regard to cancer clinical trial and treatment disruptions.
Investigators report 76 percent of trial participants had a complete response to axicabtagene ciloleucel (axi-cel), despite being resistant to other therapies.
A test that analyses free-floating DNA in the blood may be able to detect early-stage lung cancer...
Cell-weighing technique may predict which therapies a patient is most sensitive or resistant to...